Dr. Serge Gauthier

  1. McCullough, A, Chen, CD, Gordon, BA, Joseph-Mathurin, N, Jack, CR Jr, Koeppe, R et al.. Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial. Alzheimers Dement. 2025;21 (7):e70347. doi: 10.1002/alz.70347. PubMed PMID:40660741 PubMed Central PMC12260115.
  2. Gagnon, A, Manns, BH, Atanasiu, K, Lumley, D, Chakravarty, M, Gauthier, S et al.. The Neural Correlates of Delusions in Dementia: A Scoping Review. Psychogeriatrics. 2025;25 (4):e70060. doi: 10.1111/psyg.70060. PubMed PMID:40620111 .
  3. Moscoso, A, Heeman, F, Raghavan, S, Costoya-Sánchez, A, van Essen, M, Mainta, I et al.. Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity. JAMA. 2025;334 (3):229-242. doi: 10.1001/jama.2025.7817. PubMed PMID:40522652 .
  4. Abbas, S, Ferreira, PCL, Bellaver, B, Povala, G, Rohden, F, Aguzzoli, CS et al.. Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease. J Prev Alzheimers Dis. 2025;12 (7):100205. doi: 10.1016/j.tjpad.2025.100205. PubMed PMID:40473528 .
  5. Chen, CD, Franklin, EE, Li, Y, Joseph-Mathurin, N, Burns, AL, Hobbs, DA et al.. Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease. Acta Neuropathol. 2025;149 (1):57. doi: 10.1007/s00401-025-02890-7. PubMed PMID:40459787 PubMed Central PMC12133910.
  6. Bellaver, B, Povala, G, Ferreira, PCL, Bauer-Negrini, G, Lussier, FZ, Leffa, DT et al.. Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer’s disease. Alzheimers Dement. 2025;21 (5):e70209. doi: 10.1002/alz.70209. PubMed PMID:40346617 PubMed Central PMC12064411.
  7. Gauthier, S, Therriault, J, Rosa-Neto, P. Cholinergic therapy in Alzheimer disease. Handb Clin Neurol. 2025;211 :155-159. doi: 10.1016/B978-0-443-19088-9.00015-9. PubMed PMID:40340059 .
  8. Décarie-Labbé, L, Mellah, S, Dialahy, IZ, CIMA-Q Consortium , Belleville, S. Predicting cognitive change using functional, structural, and neuropsychological predictors. Brain Commun. 2025;7 (3):fcaf155. doi: 10.1093/braincomms/fcaf155. PubMed PMID:40337465 PubMed Central PMC12056721.
  9. Bezgin, G, Pascoal, TA, Therriault, J, Lussier, FZ, Servaes, S, Kang, MS et al.. Tau profiling across Alzheimer’s disease staging reveals vulnerability to disease pathophysiology. Eur J Nucl Med Mol Imaging. 2025; :. doi: 10.1007/s00259-025-07257-4. PubMed PMID:40274672 .
  10. Gauthier, S. Are Appropriate Use Recommendations useful in clinical practice?. J Prev Alzheimers Dis. 2025;12 (5):100165. doi: 10.1016/j.tjpad.2025.100165. PubMed PMID:40240188 PubMed Central PMC12184007.
  11. Aliaga, A, Therriault, J, Quispialaya, K, Aliaga, A, Kunach, P, Macedo, AC et al.. Autoradiographic comparison between [11C]PiB and [18F]AZD4694 in human brain tissue. EJNMMI Res. 2025;15 (1):30. doi: 10.1186/s13550-025-01216-8. PubMed PMID:40167827 PubMed Central PMC11961831.
  12. Bateman, RJ, Li, Y, McDade, EM, Llibre-Guerra, JJ, Clifford, DB, Atri, A et al.. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol. 2025;24 (4):316-330. doi: 10.1016/S1474-4422(25)00024-9. PubMed PMID:40120616 PubMed Central PMC12042767.
  13. Lantero-Rodriguez, J, Montoliu-Gaya, L, Ashton, NJ, Pola, I, Therriault, J, Rahmouni, N et al.. Biofluid-based staging of Alzheimer’s disease. Acta Neuropathol. 2025;149 (1):27. doi: 10.1007/s00401-025-02863-w. PubMed PMID:40095069PubMed Central PMC11913990.
  14. Tremblay, C, Rahayel, S, Pastor-Bernier, A, St-Onge, F, Vo, A, Rheault, F et al.. Uncovering atrophy progression pattern and mechanisms in individuals at risk of Alzheimer’s disease. Brain Commun. 2025;7 (2):fcaf099. doi: 10.1093/braincomms/fcaf099. PubMed PMID:40092368 PubMed Central PMC11906971.
  15. Heneka, MT, Gauthier, S, Chandekar, SA, Hviid Hahn-Pedersen, J, Bentsen, MA, Zetterberg, H et al.. Neuroinflammatory fluid biomarkers in patients with Alzheimer’s disease: a systematic literature review. Mol Psychiatry. 2025;30 (6):2783-2798. doi: 10.1038/s41380-025-02939-9. PubMed PMID:40050444 PubMed Central PMC12092255.
  16. Bateman, RJ, Li, Y, McDade, EM, Llibre-Guerra, JJ, Clifford, DB, Atri, A et al.. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial. medRxiv. 2025; :. doi: 10.1101/2024.10.29.24316289. PubMed PMID:39974075 PubMed Central PMC11838922.
  17. Arslan, B, Brum, WS, Pola, I, Therriault, J, Rahmouni, N, Stevenson, J et al.. The impact of kidney function on Alzheimer’s disease blood biomarkers: implications for predicting amyloid-β positivity. Alzheimers Res Ther. 2025;17 (1):48. doi: 10.1186/s13195-025-01692-z. PubMed PMID:39972340 PubMed Central PMC11837363.
  18. Yun, J, Shin, D, Lee, EH, Kim, JP, Ham, H, Gu, Y et al.. Temporal Dynamics and Biological Variability of Alzheimer Biomarkers. JAMA Neurol. 2025;82 (4):384-96. doi: 10.1001/jamaneurol.2024.5263. PubMed PMID:39960728 PubMed Central PMC11833660.
  19. Sogorb-Esteve, A, Weiner, S, Simrén, J, Swift, IJ, Bocchetta, M, Todd, EG et al.. Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes. Sci Transl Med. 2025;17 (784):eadm9654. doi: 10.1126/scitranslmed.adm9654. PubMed PMID:39908349 .
  20. Wang, YT, Ashton, NJ, Therriault, J, Benedet, AL, Macedo, AC, Pola, I et al.. Identify biological Alzheimer’s disease using a novel nucleic acid-linked protein immunoassay. Brain Commun. 2025;7 (1):fcaf004. doi: 10.1093/braincomms/fcaf004. PubMed PMID:39845736 PubMed Central PMC11753389.
  21. D’Amico, D, Savundranayagam, MY, Biles, R, Itzhak, I, Anderson, ND, Canadian Consortium on Neurodegeneration in Aging (CCNA) CAN-THUMBS UP Study Group et al.. Engaging older adults in the process of aging research: a multimethod study evaluating the experience and efficacy of a citizen advisory group for a dementia risk reduction program. Res Involv Engagem. 2024;10 (1):135. doi: 10.1186/s40900-024-00643-6. PubMed PMID:39731188 PubMed Central PMC11674478.
  22. Quispialaya, KM, Therriault, J, Aliaga, A, Benedet, AL, Ashton, NJ, Karikari, T et al.. Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia. Neurology. 2025;104 (2):e210211. doi: 10.1212/WNL.0000000000210211. PubMed PMID:39715476 PubMed Central PMC11666273.
  23. Chertkow, H, Phillips, N, Rockwood, K, Anderson, N, Andrew, MK, Bartha, R et al.. Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA). J Alzheimers Dis. 2024;102 (3):535-561. doi: 10.1177/13872877241290990. PubMed PMID:39636028 .
  24. Aumont, E, Bedard, MA, Bussy, A, Arias, JF, Tissot, C, Hall, BJ et al.. Hippocampal atrophy over two years in relation to tau, amyloid-β and memory in older adults. Neurobiol Aging. 2025;146 :48-57. doi: 10.1016/j.neurobiolaging.2024.11.007. PubMed PMID:39631245 .
  25. Rojas-Rozo, L, Arsenault-Lapierre, G, Dumaresq, D, Trépanier, T, Lea, P, Myers Barnett, K et al.. Unlocking Engagement: Enhancing Participation in Research With Vulnerable Populations. Int J Public Health. 2024;69 :1606705. doi: 10.3389/ijph.2024.1606705. PubMed PMID:39568528 PubMed Central PMC11576723.
  26. Therriault, J, Janelidze, S, Benedet, AL, Ashton, NJ, Arranz Martínez, J, Gonzalez-Escalante, A et al.. Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability. Nat Aging. 2024;4 (11):1529-1537. doi: 10.1038/s43587-024-00731-y. PubMed PMID:39533113 PubMed Central PMC11564087.
  27. Woo, MS, Therriault, J, Jonaitis, EM, Wilson, R, Langhough, RE, Rahmouni, N et al.. Identification of late-stage tau accumulation using plasma phospho-tau217. EBioMedicine. 2024;109 :105413. doi: 10.1016/j.ebiom.2024.105413. PubMed PMID:39500009 PubMed Central PMC11570195.
  28. Aliaga, A, Therriault, J, Quispialaya, KM, Aliaga, A, Hopewell, R, Rahmouni, N et al.. Comparison Between Brain and Cerebellar Autoradiography Using [18F]Flortaucipir, [18F]MK6240, and [18F]PI2620 in Postmortem Human Brain Tissue. J Nucl Med. 2025;66 (1):123-129. doi: 10.2967/jnumed.124.267539. PubMed PMID:39477493 .
  29. Quispialaya, KM, Therriault, J, Aliaga, A, Tissot, C, Servaes, S, Rahmouni, N et al.. Plasma phosphorylated tau181 outperforms [18F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease. Eur J Neurol. 2024;31 (12):e16255. doi: 10.1111/ene.16255. PubMed PMID:39447157 PubMed Central PMC11555153.
  30. Meilleur-Durand, S, Lévesque, M, St-Onge, F, Masellis, M, Hsiung, GR, Jarrett, P et al.. Multicenter Validation of the English Version of the Dépistage Cognitif de Québec: a Cognitive Screening Tool for Atypical Dementias. Arch Clin Neuropsychol. 2025;40 (3):718-722. doi: 10.1093/arclin/acae092. PubMed PMID:39394041 PubMed Central PMC12034515.
  31. Macedo, AC, Therriault, J, Tissot, C, Aumont, É, Servaes, S, Rahmouni, N et al.. Modeling the progression of neuropsychiatric symptoms in Alzheimer’s disease with PET-based Braak staging. Neurobiol Aging. 2024;144 :127-137. doi: 10.1016/j.neurobiolaging.2024.09.009. PubMed PMID:39326302 .
  32. Wiesman, AI, Madge, V, Fon, EA, Dagher, A, Collins, DL, Baillet, S et al.. Associations between neuromelanin depletion and cortical rhythmic activity in Parkinson’s disease. Brain. 2025;148 (3):875-885. doi: 10.1093/brain/awae295. PubMed PMID:39282945 PubMed Central PMC11884654.
  33. Belleville, S, Cuesta, M, Bier, N, Brodeur, C, Gauthier, S, Gilbert, B et al.. Five-year effects of cognitive training in individuals with mild cognitive impairment. Alzheimers Dement (Amst). 2024;16 (3):e12626. doi: 10.1002/dad2.12626. PubMed PMID:39246830 PubMed Central PMC11378074.
  34. Bieger, A, Brum, WS, Borelli, WV, Therriault, J, De Bastiani, MA, Moreira, AG et al.. Influence of Different Diagnostic Criteria on Alzheimer Disease Clinical Research. Neurology. 2024;103 (5):e209753. doi: 10.1212/WNL.0000000000209753. PubMed PMID:39167736 PubMed Central PMC11338500.
  35. Wang, YT, Therriault, J, Tissot, C, Servaes, S, Rahmouni, N, Macedo, AC et al.. Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts. Alzheimers Res Ther. 2024;16 (1):162. doi: 10.1186/s13195-024-01509-5. PubMed PMID:39034389 PubMed Central PMC11265084.
  36. Premi, E, Diano, M, Mattioli, I, Altomare, D, Cantoni, V, Bocchetta, M et al.. Impaired glymphatic system in genetic frontotemporal dementia: a GENFI study. Brain Commun. 2024;6 (4):fcae185. doi: 10.1093/braincomms/fcae185. PubMed PMID:39015769 PubMed Central PMC11249959.
  37. da Silva Castanheira, J, Wiesman, AI, Hansen, JY, Misic, B, Baillet, S, PREVENT-AD Research Group et al.. The neurophysiological brain-fingerprint of Parkinson’s disease. EBioMedicine. 2024;105 :105201. doi: 10.1016/j.ebiom.2024.105201. PubMed PMID:38908100 PubMed Central PMC11253223.
  38. Ottoy, J, Kang, MS, Tan, JXM, Boone, L, Vos de Wael, R, Park, BY et al.. Tau follows principal axes of functional and structural brain organization in Alzheimer’s disease. Nat Commun. 2024;15 (1):5031. doi: 10.1038/s41467-024-49300-2. PubMed PMID:38866759 PubMed Central PMC11169286.
  39. Howard, L, Abdelnour, C, Abner, EL, Allegri, RF, Dodge, HH, Gauthier, S et al.. Decentralized clinical trials for medications to reduce the risk of dementia: Consensus report and guidance. Alzheimers Dement. 2024;20 (7):4625-4634. doi: 10.1002/alz.13891. PubMed PMID:38824659 PubMed Central PMC11247660.
  40. Wang, YT, Ashton, NJ, Servaes, S, Nilsson, J, Woo, MS, Pascoal, TA et al.. The relation of synaptic biomarkers with Aβ, tau, glial activation, and neurodegeneration in Alzheimer’s disease. Transl Neurodegener. 2024;13 (1):27. doi: 10.1186/s40035-024-00420-1. PubMed PMID:38802928 PubMed Central PMC11131272.
  41. Wagemann, O, Liu, H, Wang, G, Shi, X, Bittner, T, Scelsi, MA et al.. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. JAMA Neurol. 2024;81 (6):582-593. doi: 10.1001/jamaneurol.2024.0991. PubMed PMID:38683602 PubMed Central PMC11059071.
  42. Walker, CS, Li, L, Baracchini, G, Tremblay-Mercier, J, Spreng, RN, PREVENT-AD Research Group et al.. Neurobehavioral Mechanisms Influencing the Association Between Generativity, the Desire to Promote Well-Being of Younger Generations, and Purpose in Life in Older Adults at Risk for Alzheimer’s Disease. J Gerontol B Psychol Sci Soc Sci. 2024;79 (6):. doi: 10.1093/geronb/gbae060. PubMed PMID:38623965 PubMed Central PMC11138215.
  43. Pasternak, M, Mirza, SS, Luciw, N, Mutsaerts, HJMM, Petr, J, Thomas, D et al.. [Not Available]. Alzheimers Dement. 2024;20 (5):3525-3542. doi: 10.1002/alz.13750. PubMed PMID:38623902 PubMed Central PMC11095434.
  44. Samra, K, Peakman, G, MacDougall, AM, Bouzigues, A, Greaves, CV, Convery, RS et al.. Extending the phenotypic spectrum assessed by the CDR plus NACC FTLD in genetic frontotemporal dementia. Alzheimers Dement (Amst). 2024;16 (2):e12571. doi: 10.1002/dad2.12571. PubMed PMID:38623386 PubMed Central PMC11016817.
  45. Macedo, AC, Therriault, J, Tissot, C, Fernandez-Arias, J, Ferreira, PCL, Vitali, P et al.. Predicting functional decline in aging and Alzheimer’s disease with PET-based Braak staging. Brain Commun. 2024;6 (2):fcae043. doi: 10.1093/braincomms/fcae043. PubMed PMID:38482373 PubMed Central PMC10935644.
  46. Therriault, J, Schindler, SE, Salvadó, G, Pascoal, TA, Benedet, AL, Ashton, NJ et al.. Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Nat Rev Neurol. 2024;20 (4):232-244. doi: 10.1038/s41582-024-00942-2. PubMed PMID:38429551 .
  47. Frederiksen, KS, Morató, X, Zetterberg, H, Gauthier, S, Boada, M, Pytel, V et al.. Focusing on Earlier Management of Alzheimer Disease: Expert Opinion Based on a Modified Nominal Group Technique. Alzheimer Dis Assoc Disord. ;38 (1):1-7. doi: 10.1097/WAD.0000000000000600. PubMed PMID:38300883 .
  48. Linnemann, C, Wilke, C, Mengel, D, Zetterberg, H, Heller, C, Kuhle, J et al.. NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study. J Neurol Neurosurg Psychiatry. 2024;95 (9):822-828. doi: 10.1136/jnnp-2023-332464. PubMed PMID:38253362 PubMed Central PMC11347244.
  49. Benussi, A, Premi, E, Grassi, M, Alberici, A, Cantoni, V, Gazzina, S et al.. Diagnostic accuracy of research criteria for prodromal frontotemporal dementia. Alzheimers Res Ther. 2024;16 (1):10. doi: 10.1186/s13195-024-01383-1. PubMed PMID:38216961 PubMed Central PMC10785469.
  50. Therriault, J, Woo, MS, Salvadó, G, Gobom, J, Karikari, TK, Janelidze, S et al.. Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology. Mol Neurodegener. 2024;19 (1):2. doi: 10.1186/s13024-023-00689-2. PubMed PMID:38185677 PubMed Central PMC10773025.
  51. Frank, A, Ismail, Z, Wilson, M, Gauthier, S, Verret, L, Hsiung, GR et al.. Health System Change for Alzheimer’s Disease-Modifying Therapies in Canada: Beginning the Discussion. Can J Neurol Sci. 2023; :1-9. doi: 10.1017/cjn.2023.322. PubMed PMID:38052729 .
  52. Aumont, E, Bussy, A, Bedard, MA, Bezgin, G, Therriault, J, Savard, M et al.. Hippocampal subfield associations with memory depend on stimulus modality and retrieval mode. Brain Commun. 2023;5 (6):fcad309. doi: 10.1093/braincomms/fcad309. PubMed PMID:38035364 PubMed Central PMC10681971.
  53. Schaffer Aguzzoli, C, Ferreira, PCL, Povala, G, Ferrari-Souza, JP, Bellaver, B, Soares Katz, C et al.. Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease. JAMA Netw Open. 2023;6 (11):e2345175. doi: 10.1001/jamanetworkopen.2023.45175. PubMed PMID:38010651 PubMed Central PMC10682836.
  54. Woo, MS, Nilsson, J, Therriault, J, Rahmouni, N, Brinkmalm, A, Benedet, AL et al.. 14-3-3 -reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2. J Neuroinflammation. 2023;20 (1):278. doi: 10.1186/s12974-023-02962-z. PubMed PMID:38001539 PubMed Central PMC10675887.
  55. Quesnel, MJ, Labonté, A, Picard, C, Zetterberg, H, Blennow, K, Brinkmalm, A et al.. Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains. Brain. 2024;147 (5):1680-1695. doi: 10.1093/brain/awad398. PubMed PMID:37992295 PubMed Central PMC11068109.
  56. Wang, YT, Therriault, J, Servaes, S, Tissot, C, Rahmouni, N, Macedo, AC et al.. Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females. Brain. 2024;147 (4):1497-1510. doi: 10.1093/brain/awad397. PubMed PMID:37988283 PubMed Central PMC10994548.
  57. Ullgren, A, Öijerstedt, L, Olofsson, J, Bergström, S, Remnestål, J, van Swieten, JC et al.. Altered plasma protein profiles in genetic FTD – a GENFI study. Mol Neurodegener. 2023;18 (1):85. doi: 10.1186/s13024-023-00677-6. PubMed PMID:37968725 PubMed Central PMC10648335.
  58. Parent, O, Bussy, A, Devenyi, GA, Dai, A, Costantino, M, Tullo, S et al.. Assessment of white matter hyperintensity severity using multimodal magnetic resonance imaging. Brain Commun. 2023;5 (6):fcad279. doi: 10.1093/braincomms/fcad279. PubMed PMID:37953840 PubMed Central PMC10636521.
  59. Woo, MS, Tissot, C, Lantero-Rodriguez, J, Snellman, A, Therriault, J, Rahmouni, N et al.. Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals. Alzheimers Dement. 2024;20 (2):1166-1174. doi: 10.1002/alz.13528. PubMed PMID:37920945 PubMed Central PMC10916953.
  60. Rojas-Rozo, L, Lee, L, Khanassov, V, Sivananthan, S, Ismail, Z, Gauthier, S et al.. Latest Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: What’s in It for Primary Care?. Can J Aging. 2024;43 (2):185-196. doi: 10.1017/S0714980823000521. PubMed PMID:37855225 .
  61. Guilliot, S, Gauthier, S, Touchon, J, Soto, ME. Lithium, a Treatment Option for Alzheimer’s Disease? A Review of Existing Evidence and Discussion on Future Perspectives. J Alzheimers Dis. 2023;96 (2):473-482. doi: 10.3233/JAD-230568. PubMed PMID:37781804 .
  62. Ferrari-Souza, JP, Bellaver, B, Ferreira, PCL, Benedet, AL, Povala, G, Lussier, FZ et al.. APOEε4 potentiates amyloid β effects on longitudinal tau pathology. Nat Aging. 2023;3 (10):1210-1218. doi: 10.1038/s43587-023-00490-2. PubMed PMID:37749258 PubMed Central PMC10592050.
  63. Wittich, W, Kröger, E, Aubin, G, Fadhlaoui, A, Anderson, ND, Ben Gaied, N et al.. Using co-creation focus groups to customise a remote multidomain programme designed to increase dementia literacy. BMJ Open. 2023;13 (9):e074555. doi: 10.1136/bmjopen-2023-074555. PubMed PMID:37709333 PubMed Central PMC10921908.
  64. Gauthier, S. Can we improve care of people with mild cognitive impairment or dementia in Canada?. Can J Neurol Sci. 2023; :1-3. doi: 10.1017/cjn.2023.283. PubMed PMID:37655739 .
  65. Wang, YT, Rosa-Neto, P, Gauthier, S. Advanced brain imaging for the diagnosis of Alzheimer disease. Curr Opin Neurol. 2023;36 (5):481-490. doi: 10.1097/WCO.0000000000001198. PubMed PMID:37639461 .
  66. Cinalioglu, K, Lavín, P, Bein, M, Lesage, M, Gruber, J, Se, J et al.. Effects of virtual reality guided meditation in older adults: the protocol of a pilot randomized controlled trial. Front Psychol. 2023;14 :1083219. doi: 10.3389/fpsyg.2023.1083219. PubMed PMID:37575420 PubMed Central PMC10421698.
  67. Ferreira, PCL, Therriault, J, Tissot, C, Ferrari-Souza, JP, Benedet, AL, Povala, G et al.. Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimers Dement. 2023;19 (10):4463-4474. doi: 10.1002/alz.13393. PubMed PMID:37534889 PubMed Central PMC10592380.
  68. Samra, K, MacDougall, AM, Bouzigues, A, Bocchetta, M, Cash, DM, Greaves, CV et al.. Prodromal language impairment in genetic frontotemporal dementia within the GENFI cohort. J Neurol Sci. 2023;451 :120711. doi: 10.1016/j.jns.2023.120711. PubMed PMID:37348248 .
  69. Macedo, AC, Tissot, C, Therriault, J, Servaes, S, Wang, YT, Fernandez-Arias, J et al.. The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework. J Nucl Med. 2023;64 (8):1171-1178. doi: 10.2967/jnumed.122.265200. PubMed PMID:37321820 PubMed Central PMC10394315.
  70. Fernández Arias, J, Therriault, J, Thomas, E, Lussier, FZ, Bezgin, G, Tissot, C et al.. Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer’s disease. Brain Commun. 2023;5 (3):fcad146. doi: 10.1093/braincomms/fcad146. PubMed PMID:37252014 PubMed Central PMC10213301.
  71. Bellaver, B, Povala, G, Ferreira, PCL, Ferrari-Souza, JP, Leffa, DT, Lussier, FZ et al.. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease. Nat Med. 2023;29 (7):1775-1781. doi: 10.1038/s41591-023-02380-x. PubMed PMID:37248300 PubMed Central PMC10353939.
  72. Ai, M, Morris, TP, Zhang, J, de la Colina, AN, Tremblay-Mercier, J, Villeneuve, S et al.. Resting-state MRI functional connectivity as a neural correlate of multidomain lifestyle adherence in older adults at risk for Alzheimer’s disease. Sci Rep. 2023;13 (1):7487. doi: 10.1038/s41598-023-32714-1. PubMed PMID:37160915 PubMed Central PMC10170147.
  73. Therriault, J, Pascoal, TA, Lussier, FZ, Tissot, C, Chamoun, M, Bezgin, G et al.. Biomarker modeling of Alzheimer’s disease using PET-based Braak staging. Nat Aging. 2022;2 (6):526-535. doi: 10.1038/s43587-022-00204-0. PubMed PMID:37118445 PubMed Central PMC10154209.
  74. Therriault, J, Servaes, S, Tissot, C, Rahmouni, N, Ashton, NJ, Benedet, AL et al.. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer’s disease. Alzheimers Dement. 2023;19 (11):4967-4977. doi: 10.1002/alz.13026. PubMed PMID:37078495 PubMed Central PMC10587362.
  75. Ferrari-Souza, JP, Lussier, FZ, Leffa, DT, Therriault, J, Tissot, C, Bellaver, B et al.. APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles. Sci Adv. 2023;9 (14):eade1474. doi: 10.1126/sciadv.ade1474. PubMed PMID:37018391 PubMed Central PMC10075966.
  76. Chen, CD, McCullough, A, Gordon, B, Joseph-Mathurin, N, Flores, S, McKay, NS et al.. Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2023;50 (9):2669-2682. doi: 10.1007/s00259-023-06209-0. PubMed PMID:37017737 PubMed Central PMC10330155.
  77. Bocchetta, M, Todd, EG, Bouzigues, A, Cash, DM, Nicholas, JM, Convery, RS et al.. Structural MRI predicts clinical progression in presymptomatic genetic frontotemporal dementia: findings from the GENetic Frontotemporal dementia Initiative cohort. Brain Commun. 2023;5 (2):fcad061. doi: 10.1093/braincomms/fcad061. PubMed PMID:36970046 PubMed Central PMC10036293.
  78. Samra, K, MacDougall, AM, Bouzigues, A, Bocchetta, M, Cash, DM, Greaves, CV et al.. Genetic forms of primary progressive aphasia within the GENetic Frontotemporal dementia Initiative (GENFI) cohort: comparison with sporadic primary progressive aphasia. Brain Commun. 2023;5 (2):fcad036. doi: 10.1093/braincomms/fcad036. PubMed PMID:36938528 PubMed Central PMC10019761.
  79. Bellaver, B, Puig-Pijoan, A, Ferrari-Souza, JP, Leffa, DT, Lussier, FZ, Ferreira, PCL et al.. Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology. Alzheimers Dement. 2023;19 (9):3815-3825. doi: 10.1002/alz.13014. PubMed PMID:36919582 PubMed Central PMC10502181.
  80. Premi, E, Pengo, M, Mattioli, I, Cantoni, V, Dukart, J, Gasparotti, R et al.. Early neurotransmitters changes in prodromal frontotemporal dementia: A GENFI study. Neurobiol Dis. 2023;179 :106068. doi: 10.1016/j.nbd.2023.106068. PubMed PMID:36898614 .
  81. Bussy, A, Levy, JP, Best, T, Patel, R, Cupo, L, Van Langenhove, T et al.. Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia. Hum Brain Mapp. 2023;44 (7):2684-2700. doi: 10.1002/hbm.26220. PubMed PMID:36895129 PubMed Central PMC10089095.
  82. Ferreira, PCL, Ferrari-Souza, JP, Tissot, C, Bellaver, B, Leffa, DT, Lussier, F et al.. Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. Neurology. 2023;101 (1):38-45. doi: 10.1212/WNL.0000000000207115. PubMed PMID:36878697 PubMed Central PMC10351303.
  83. Tedeschi Dauar, M, Pascoal, TA, Therriault, J, Rowley, J, Mohaddes, S, Shin, M et al.. Dynamic Amyloid and Metabolic Signatures of Delayed Recall Performance within the Clinical Spectrum of Alzheimer’s Disease. Brain Sci. 2023;13 (2):. doi: 10.3390/brainsci13020232. PubMed PMID:36831775 PubMed Central PMC9954101.
  84. Intzandt, B, Sanami, S, Huck, J, PREVENT-AD Research group, Villeneuve, S, Bherer, L et al.. Sex-specific relationships between obesity, physical activity, and gray and white matter volume in cognitively unimpaired older adults. Geroscience. 2023;45 (3):1869-1888. doi: 10.1007/s11357-023-00734-4. PubMed PMID:36781598 PubMed Central PMC10400512.
  85. Pascoal, T, Bellaver, B, Povala, G, Ferreira, P, Ferrari-Souza, JP, Leffa, D et al.. Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease. Res Sq. 2023; :. doi: 10.21203/rs.3.rs-2507179/v1. PubMed PMID:36778243 PubMed Central PMC9915798.
  86. Pascoal, TA, Leuzy, A, Therriault, J, Chamoun, M, Lussier, F, Tissot, C et al.. Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer’s disease. Alzheimers Dement (Amst). 2023;15 (1):e12390. doi: 10.1002/dad2.12390. PubMed PMID:36733847 PubMed Central PMC9886860.
  87. Jia, J, Zhao, T, Liu, Z, Liang, Y, Li, F, Li, Y et al.. Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study. BMJ. 2023;380 :e072691. doi: 10.1136/bmj-2022-072691. PubMed PMID:36696990 PubMed Central PMC9872850.
  88. Kwan, ATH, Arfaie, S, Therriault, J, Azizi, Z, Lussier, FZ, Tissot, C et al.. Medial temporal tau predicts memory decline in cognitively unimpaired elderly. Brain Commun. 2023;5 (1):fcac325. doi: 10.1093/braincomms/fcac325. PubMed PMID:36627889 PubMed Central PMC9814120.
  89. Samra, K, Macdougall, A, Peakman, G, Bouzigues, A, Bocchetta, M, Cash, DM et al.. Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for Clinical Rating Scales. J Neurol Neurosurg Psychiatry. 2023;94 (5):357-368. doi: 10.1136/jnnp-2022-330152. PubMed PMID:36627201 PubMed Central PMC10176351.
  90. Therriault, J, Gauthier, S, Rosa-Neto, P. Applications of Alzheimer’s disease staging to clinical trials. Aging (Albany NY). 2023;15 (1):4-5. doi: 10.18632/aging.204482. PubMed PMID:36622284 PubMed Central PMC9876645.
  91. Liu, W, Gauthier, S, Jia, J. Alzheimer’s disease: current status and perspective. Sci Bull (Beijing). 2022;67 (24):2494-2497. doi: 10.1016/j.scib.2022.12.006. PubMed PMID:36604022 .
  92. Samra, K, MacDougall, AM, Bouzigues, A, Bocchetta, M, Cash, DM, Greaves, CV et al.. Language impairment in the genetic forms of behavioural variant frontotemporal dementia. J Neurol. 2023;270 (4):1976-1988. doi: 10.1007/s00415-022-11512-1. PubMed PMID:36538154 PubMed Central PMC10025186.
  93. Therriault, J, Vermeiren, M, Servaes, S, Tissot, C, Ashton, NJ, Benedet, AL et al.. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023;80 (2):188-199. doi: 10.1001/jamaneurol.2022.4485. PubMed PMID:36508198 PubMed Central PMC9856704.
  94. Finger, E, Malik, R, Bocchetta, M, Coleman, K, Graff, C, Borroni, B et al.. Neurodevelopmental effects of genetic frontotemporal dementia in young adult mutation carriers. Brain. 2023;146 (5):2120-2131. doi: 10.1093/brain/awac446. PubMed PMID:36458975 .
  95. Grazia, A, Altomare, D, Preis, L, Monsch, AU, Cappa, SF, Gauthier, S et al.. Feasibility of a standard cognitive assessment in European academic memory clinics. Alzheimers Dement. 2023;19 (6):2276-2286. doi: 10.1002/alz.12830. PubMed PMID:36453876 .
  96. Pérez-Millan, A, Borrego-Écija, S, van Swieten, JC, Jiskoot, L, Moreno, F, Laforce, R et al.. Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study. J Neurol. 2023;270 (3):1573-1586. doi: 10.1007/s00415-022-11435-x. PubMed PMID:36443488 .
  97. Iturria-Medina, Y, Adewale, Q, Khan, AF, Ducharme, S, Rosa-Neto, P, O’Donnell, K et al.. Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer’s disease progression and heterogeneity. Sci Adv. 2022;8 (46):eabo6764. doi: 10.1126/sciadv.abo6764. PubMed PMID:36399579 PubMed Central PMC9674284.
  98. Tissot, C, Servaes, S, Lussier, FZ, Ferrari-Souza, JP, Therriault, J, Ferreira, PCL et al.. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions. J Nucl Med. 2023;64 (3):452-459. doi: 10.2967/jnumed.122.264434. PubMed PMID:36396455 PubMed Central PMC10071794.
  99. Samra, K, MacDougall, AM, Peakman, G, Bouzigues, A, Bocchetta, M, Cash, DM et al.. Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales. J Neurol. 2023;270 (3):1466-1477. doi: 10.1007/s00415-022-11442-y. PubMed PMID:36385202 PubMed Central PMC9971048.
  100. Whiteside, DJ, Malpetti, M, Jones, PS, Ghosh, BCP, Coyle-Gilchrist, I, van Swieten, JC et al.. Temporal dynamics predict symptom onset and cognitive decline in familial frontotemporal dementia. Alzheimers Dement. 2023;19 (5):1947-1962. doi: 10.1002/alz.12824. PubMed PMID:36377606 PubMed Central PMC7614527.

Search PubMed